LAG3 and cancer: LAG-3, an immunosuppressive checkpoint molecule, expressed in lymphocytes and its ligand GAL-3, has been identified on EC cells, particularly in nonmethylated dMMR cancers, supportting a role for immunotherapies targeting LAG-3 and/or GAL-3 in a subset of EC [331].